SCRI-CAR22v2

N/A

Report date: 2022/12/03 23:07:35

Base Information

Drug NameSCRI-CAR22v2

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-CD22

TargetsCD22

Therapy Area/IndicationsLymphomaLeukemia

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesSeattle Children'S Hospital

China Registration ClassN/A

Develop Information

Active CompaniesSeattle Children'S Hospital

Inactive CompaniesN/A

Active IndicationsLymphomaLeukemia

Inactive IndicationsN/A

Other Information

ATC CodeN/A